| Protocol Title |
Study # |
Study Group |
| A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 CM) Peripheral Non-Small Cell Lung Cancer |
CALGB 140503 |
SIU Thoracic |
| A Phase III Study of Sublohbar Resection Versus Sublobar Resection + Brachytherapy in High Risk Patients With Non-Small Cell Lung Cancer |
Z4032 |
SIU Thoracic |
| Brachytherapy Following Sublobar Resection in High Risk Patients With Stage I Non-Small Cell Lung Carcinoma |
I 125 |
SIU Thoracic |
|
Adjuvant Non-Small Cell Lung Cancer
|
| Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC) |
SWOG S0720 |
CICCOP |
| A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4cm)-IIIA Non-Small Lung Cancer (NSCLC) |
ECOG E1505 |
CICCOP |
|
Locally Advanced & Metastatic
|
| Randomized Phase 2 Study of Cisplatin / Permetrexed with or without Axitinib (AG-013736) as First-Line Treatment for Patients with Non-Squamous Non-Small Cell Lung Cancer |
08-103 |
SCCI |
| Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB / IV Non-Small Cell Lung Cancer |
CTSU-CALGB 30607 |
CICCOP |
| A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (RHUMAB VEGF; NSC 704865) in Never-Smokers With Stage IIIB and IV Primary NSCLC Adenocarcinomas |
SWOG S0636 |
CICCOP |
| A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non- Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib |
NCCTG N0723 |
CICCOP |
| Antigen Specific Cancer Immunotherapeutic (ASCI) study |
GSK MAGE- A-3 |
SIU Thoracic |
| A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2) Selected by Serum Proteomics |
SWOG S0709 |
CICCOP |
| Protocol Z4051: A Phase II Study of Neoadjuvant Therapy with Cisplatin, Docetaxel, Panitumumab, Plus Radiation Therapy Followed by Surgery in Patients with Locally Advanced Adenocarcinoma of the Distal Esophagus |
09-010 |
SIU Thoracic |
| A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) |
SWOG S0819 |
CICCOP |
|
Bronchioalveolar Cancer (BAC)
|
| A Phase II Trial of the Combination of OSI-774 (ERLOTINIB; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features (ADENOBAC) |
SWOG S0635 |
CICCOP |
| Small Cell |
| Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide |
CTSU-CALGB 30610 |
CICCOP |
| A Randomized Phase II Trial of Weekly Topotecan With and Without AVE0005 (Aflibercept; NSC-724770) in Patients With Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC) |
SWOG S0802 |
CICCOP |
| A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMCA12 for Patients With Extensive Stage Small Cell Lung Cancer |
ECOG E1508 |
CICCOP |
|
Mesothelioma, 2nd Line |
| Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM) |
SWOG S0722 |
CICCOP |
| Cancer Control |
| Phase III Chemoprevention Trial of Selenium Supplementation in Persons With Resected Stage I Non-Small Cell Lung Cancer |
ECOG E5597 |
CICCOP |
| Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men *Smoking Strata Closed to Entry |
SWOG S0424 |
CICCOP |
| Compare the Outcomes of Four Groups of Lung cancer Patients Who Consent to Participate |
Behavior Outcomes Trial |
SIU Thoracic |
